Company News
Intellia Stock Jumps 8% on FDA Review
Intellia Therapeutics shares rose about 8% after the FDA accepted its BLA for lonvo‑z with Priority Review.
The FDA set a PDUFA target action date of March 10 2027 and indicated no advisory committee
